Statement: adverse events linked to heart conditions and infections are recorded consistently in primary and secondary clinical trials
Primary_evidence: Adverse Events 1:   Total: 0/655 (0.00%) Adverse Events 2:   Total: 0/580 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/15 (0.00%) Adverse Events 2:   Total: 0/16 (0.00%)